Symbols / NKGN $0.06 +0.00%
NKGN Chart
About
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors. It has a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to develop, conduct clinical trials, obtain regulatory approvals, manufacture, and commercialize the company's autologous NK cell therapy product candidates for central nervous system and autoimmune conditions in Japan. The company also has a license agreement with NKMAX Co., Ltd. for the research and development of its NK cell program. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.84M |
| Enterprise Value | 46.02M | Income | -23.55M | Sales | — |
| Book/sh | -0.98 | Cash/sh | 6000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 26 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | -0.06 | P/C | — |
| EV/EBITDA | -2.02 | EV/Sales | — | Quick Ratio | 0.00 |
| Current Ratio | 0.05 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.33 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -93.33% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 130.60M |
| Shs Float | 65.51M | Short Float | 5.53% | Short Ratio | 0.38 |
| Short Interest | — | 52W High | 0.46 | 52W Low | 0.00 |
| Beta | 0.94 | Avg Volume | 4.25K | Volume | 200.00 |
| Target Price | — | Recom | None | Prev Close | $0.06 |
| Price | $0.06 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.06
Latest analyst target
3. DCF / Fair value
$-2.89
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.06
Low
—
High
—
Mean
—
- Alzheimer’s cell therapy trial data to be unveiled at AD/PD 2026 - Stock Titan ue, 10 Mar 2026 12
- Leading Alzheimer’s doctor joins NKGen on NK cell therapy - Stock Titan hu, 22 Jan 2026 08
- NKGN - NKGen Biotech Inc Latest Stock News & Market Updates - Stock Titan Sun, 22 Feb 2026 16
- NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented - Yahoo Finance ue, 04 Mar 2025 08
- What is the current Price Target and Forecast for NKGen Biotech, Inc. (NKGN) - Zacks Investment Research ue, 16 Apr 2024 15
- NKGN - NKGen Biotech Inc Latest Stock News & Market Updates - Stock Titan Mon, 28 Jul 2025 07
- Form 10-K Filed Oct 8, 2025 — NKGen Biotech clarifies OTC Expert Market quotes; Common Stock remains tradable - Stock Titan hu, 09 Oct 2025 07
- Should I buy NKGen Biotech, Inc. (NKGN) - Zacks Investment Research ue, 12 Mar 2024 04
- NKGen Biotech, Inc. Announces Closing of Business Combination - Yahoo Finance Mon, 02 Oct 2023 07
- NKGN Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 01
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 19669552 | 5605822 | — | Purchase at price 0.28 per share. | CFIC-2015 NV FAMILY INVESTMENTS LLC., | Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-27 00:00:00 | D |
| 1 | 20849725 | 2650000 | — | Purchase at price 0.13 per share. | SONG PAUL Y | Chief Executive Officer | — | 2025-05-05 00:00:00 | D |
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -5.90M | 0.00 | 0.00 | |
| TaxRateForCalcs | 0.21 | 0.21 | 0.27 | |
| NormalizedEBITDA | -52.90M | -23.23M | -20.70M | |
| TotalUnusualItems | -28.10M | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | -28.10M | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -82.95M | -26.75M | -23.27M | |
| ReconciledDepreciation | 1.20M | 1.21M | 1.24M | |
| ReconciledCostOfRevenue | 0.00 | 18.00K | 30.00K | |
| EBITDA | -81.00M | -23.23M | -20.70M | |
| EBIT | -82.20M | -24.44M | -21.95M | |
| NetInterestIncome | -25.22M | -2.31M | -1.31M | |
| InterestExpense | 745.00K | 2.31M | 1.31M | |
| NormalizedIncome | -60.75M | -26.75M | -23.27M | |
| NetIncomeFromContinuingAndDiscontinuedOperation | -82.95M | -26.75M | -23.27M | |
| TotalExpenses | 29.75M | 24.42M | 22.29M | |
| TotalOperatingIncomeAsReported | -29.75M | -24.35M | -21.86M | |
| DilutedAverageShares | 28.83M | 15.43M | 32.60M | 32.60M |
| BasicAverageShares | 28.83M | 15.43M | 32.60M | 32.60M |
| DilutedEPS | -1.54 | -5.38 | -0.82 | -0.71 |
| BasicEPS | -1.54 | -5.38 | -0.82 | -0.71 |
| DilutedNIAvailtoComStockholders | -82.95M | -26.75M | -23.27M | |
| NetIncomeCommonStockholders | -82.95M | -26.75M | -23.27M | |
| NetIncome | -82.95M | -26.75M | -23.27M | |
| NetIncomeIncludingNoncontrollingInterests | -82.95M | -26.75M | -23.27M | |
| NetIncomeContinuousOperations | -82.95M | -26.75M | -23.27M | |
| TaxProvision | 7.00K | 7.00K | 5.00K | |
| PretaxIncome | -82.95M | -26.75M | -23.26M | |
| OtherIncomeExpense | -27.98M | -95.00K | -84.00K | |
| OtherNonOperatingIncomeExpenses | 120.00K | -95.00K | -84.00K | |
| SpecialIncomeCharges | -3.33M | 0.00 | ||
| RestructuringAndMergernAcquisition | 3.33M | 0.00 | ||
| GainOnSaleOfSecurity | -24.77M | |||
| NetNonOperatingInterestIncomeExpense | -25.22M | -2.31M | -1.31M | |
| InterestExpenseNonOperating | 745.00K | 2.31M | 1.31M | |
| OperatingIncome | -29.75M | -24.35M | -21.86M | |
| OperatingExpense | 29.75M | 24.41M | 22.26M | |
| ResearchAndDevelopment | 15.67M | 16.75M | 14.67M | |
| SellingGeneralAndAdministration | 14.08M | 7.66M | 7.58M | |
| GeneralAndAdministrativeExpense | 14.08M | 7.66M | 7.58M | |
| OtherGandA | 14.08M | 7.66M | 7.58M | |
| GrossProfit | 0.00 | 59.00K | 396.00K | |
| CostOfRevenue | 0.00 | 18.00K | 30.00K | |
| TotalRevenue | 0.00 | 77.00K | 426.00K | |
| OperatingRevenue | 0.00 | 77.00K | 426.00K |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 21.89M | 21.89M | 21.89M |
| ShareIssued | 21.89M | 21.89M | 21.89M |
| NetDebt | 19.89M | 11.54M | 50.80M |
| TotalDebt | 19.92M | 12.03M | 51.97M |
| TangibleBookValue | -58.78M | 1.47M | -38.14M |
| InvestedCapital | -38.77M | 13.22M | 13.10M |
| WorkingCapital | -37.52M | -14.39M | -55.13M |
| NetTangibleAssets | -58.78M | 1.47M | -38.14M |
| CapitalLeaseObligations | 0.00 | 379.00K | 818.00K |
| CommonStockEquity | -58.69M | 1.56M | -38.05M |
| TotalCapitalization | -48.76M | 1.56M | -38.05M |
| TotalEquityGrossMinorityInterest | -58.69M | 1.56M | -38.05M |
| StockholdersEquity | -58.69M | 1.56M | -38.05M |
| OtherEquityInterest | -18.29M | ||
| RetainedEarnings | -162.13M | -79.18M | -52.42M |
| AdditionalPaidInCapital | 121.73M | 80.74M | 14.36M |
| CapitalStock | 2.00K | 1.00K | 14.00K |
| CommonStock | 2.00K | 1.00K | 14.00K |
| TotalLiabilitiesNetMinorityInterest | 75.17M | 14.77M | 56.12M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 35.72M | 26.00K | 379.00K |
| DerivativeProductLiabilities | 25.76M | 0.00 | |
| NonCurrentDeferredLiabilities | 33.00K | 26.00K | 19.00K |
| NonCurrentDeferredTaxesLiabilities | 33.00K | 26.00K | 19.00K |
| LongTermDebtAndCapitalLeaseObligation | 9.93M | 0.00 | 360.00K |
| LongTermCapitalLeaseObligation | 0.00 | 360.00K | |
| LongTermDebt | 9.93M | ||
| CurrentLiabilities | 39.45M | 14.74M | 55.74M |
| OtherCurrentLiabilities | 15.86M | 55.00K | 63.00K |
| CurrentDebtAndCapitalLeaseObligation | 9.99M | 12.03M | 51.61M |
| CurrentCapitalLeaseObligation | 0.00 | 379.00K | 458.00K |
| CurrentDebt | 9.99M | 11.65M | 51.15M |
| OtherCurrentBorrowings | 5.00M | 11.65M | 51.15M |
| LineOfCredit | 4.99M | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 911.00K | 291.00K | 240.00K |
| PayablesAndAccruedExpenses | 12.69M | 2.36M | 3.83M |
| CurrentAccruedExpenses | 1.36M | 1.36M | 248.00K |
| Payables | 11.33M | 1.00M | 3.58M |
| OtherPayable | 84.00K | 27.00K | |
| DuetoRelatedPartiesCurrent | 202.00K | 0.00 | 1.87M |
| AccountsPayable | 11.04M | 975.00K | 1.71M |
| TotalAssets | 16.48M | 16.33M | 18.07M |
| TotalNonCurrentAssets | 14.55M | 15.98M | 17.46M |
| GoodwillAndOtherIntangibleAssets | 92.00K | 97.00K | 89.00K |
| OtherIntangibleAssets | 92.00K | 97.00K | 89.00K |
| NetPPE | 14.46M | 15.88M | 17.37M |
| AccumulatedDepreciation | -3.83M | -2.69M | -1.53M |
| GrossPPE | 18.28M | 18.57M | 18.90M |
| Leases | 52.00K | 52.00K | 52.00K |
| OtherProperties | 4.00M | 4.37M | 4.71M |
| MachineryFurnitureEquipment | 878.00K | 806.00K | 806.00K |
| BuildingsAndImprovements | 8.32M | 8.32M | 8.31M |
| LandAndImprovements | 5.03M | 5.03M | 5.03M |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.93M | 350.00K | 612.00K |
| OtherCurrentAssets | 63.00K | 4.00K | 22.00K |
| RestrictedCash | 250.00K | 0.00 | |
| PrepaidAssets | 1.56M | 133.00K | 172.00K |
| Receivables | 26.00K | 96.00K | 67.00K |
| OtherReceivables | 26.00K | 67.00K | 67.00K |
| AccountsReceivable | 0.00 | 29.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 26.00K | 117.00K | 351.00K |
| CashAndCashEquivalents | 26.00K | 117.00K | 351.00K |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -22.00M | -22.72M | -20.01M |
| RepaymentOfDebt | -300.00K | -675.00K | -404.00K |
| IssuanceOfDebt | 26.51M | 23.00M | 20.50M |
| IssuanceOfCapitalStock | 1.67M | 0.00 | 63.00K |
| CapitalExpenditure | -48.00K | -163.00K | -459.00K |
| InterestPaidSupplementalData | 241.00K | 35.00K | |
| EndCashPosition | 276.00K | 117.00K | 351.00K |
| BeginningCashPosition | 117.00K | 351.00K | 199.00K |
| ChangesInCash | 159.00K | -234.00K | 152.00K |
| FinancingCashFlow | 22.16M | 22.49M | 20.16M |
| CashFlowFromContinuingFinancingActivities | 22.16M | 22.49M | 20.16M |
| NetOtherFinancingCharges | -15.94M | ||
| ProceedsFromStockOptionExercised | 10.22M | 161.00K | 63.00K |
| NetCommonStockIssuance | 1.67M | 0.00 | 63.00K |
| CommonStockIssuance | 1.67M | 0.00 | 63.00K |
| NetIssuancePaymentsOfDebt | 26.21M | 22.32M | 20.10M |
| NetShortTermDebtIssuance | 9.99M | 23.00M | 20.50M |
| ShortTermDebtPayments | -300.00K | 0.00 | -404.00K |
| ShortTermDebtIssuance | 10.29M | 23.00M | 20.50M |
| NetLongTermDebtIssuance | 16.21M | -675.00K | -404.00K |
| LongTermDebtPayments | 0.00 | -675.00K | -404.00K |
| LongTermDebtIssuance | 16.21M | 0.00 | |
| InvestingCashFlow | -48.00K | -163.00K | -459.00K |
| CashFlowFromContinuingInvestingActivities | -48.00K | -163.00K | -459.00K |
| NetPPEPurchaseAndSale | 0.00 | -101.00K | -403.00K |
| PurchaseOfPPE | 0.00 | -101.00K | -403.00K |
| CapitalExpenditureReported | -48.00K | -62.00K | -56.00K |
| OperatingCashFlow | -21.95M | -22.56M | -19.55M |
| CashFlowFromContinuingOperatingActivities | -21.95M | -22.56M | -19.55M |
| ChangeInWorkingCapital | 2.23M | 30.00K | 932.00K |
| ChangeInOtherWorkingCapital | -14.00K | -4.00K | 26.00K |
| ChangeInOtherCurrentLiabilities | -379.00K | -437.00K | -116.00K |
| ChangeInPayablesAndAccruedExpense | 3.99M | 443.00K | 959.00K |
| ChangeInPrepaidAssets | -1.40M | 57.00K | -48.00K |
| ChangeInReceivables | 29.00K | -29.00K | 111.00K |
| ChangesInAccountReceivables | 29.00K | -29.00K | 111.00K |
| OtherNonCashItems | 4.20M | 2.71M | 1.30M |
| StockBasedCompensation | 4.13M | 69.00K | 93.00K |
| UnrealizedGainLossOnInvestmentSecurities | 24.33M | 177.00K | 143.00K |
| DepreciationAmortizationDepletion | 1.20M | 1.21M | 1.24M |
| DepreciationAndAmortization | 1.20M | 1.21M | 1.24M |
| Depreciation | 1.65M | 1.24M | |
| OperatingGainsLosses | 24.92M | ||
| GainLossOnInvestmentSecurities | 24.92M | ||
| NetIncomeFromContinuingOperations | -82.95M | -26.75M | -23.27M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for NKGN
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|